The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

The FDA has removed the recommended pause in the use of Valneva’s chikungunya vaccine Ixchiq in individuals aged 60 years and older.

Valneva SE ( NASDAQ: VALN) said on Thursday that the FDA has lifted its pause on the use of its chikungunya vaccine, Ixchiq, ...

The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with ...

Ixchiq now has a warning about its use among elderly people with multiple underlying health conditions after postmarketing ...

French vaccines developer Valneva announced that the US Food and Drug Administration (FDA) has removed its recommended pause ...

The Ixchiq vaccine was approved for adults 18 and up at risk of exposure to the virus in 2023, when the CDC had recorded 152 ...

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ® in individuals 60 years of age and ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

The CDC warns about the mosquito-borne chikungunya virus, which is gaining prevalence in South Asia and Europe, and affecting U.S. travelers.